Does TARLATAMAB-DLLE Cause Disease progression? 34 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 34 reports of Disease progression have been filed in association with TARLATAMAB-DLLE (IMDELLTRA (AMG757)). This represents 4.2% of all adverse event reports for TARLATAMAB-DLLE.
34
Reports of Disease progression with TARLATAMAB-DLLE
4.2%
of all TARLATAMAB-DLLE reports
9
Deaths
5
Hospitalizations
How Dangerous Is Disease progression From TARLATAMAB-DLLE?
Of the 34 reports, 9 (26.5%) resulted in death, 5 (14.7%) required hospitalization.
Is Disease progression Listed in the Official Label?
Yes, Disease progression is listed as a known adverse reaction in the official FDA drug label for TARLATAMAB-DLLE.
What Other Side Effects Does TARLATAMAB-DLLE Cause?
Cytokine release syndrome (274)
Immune effector cell-associated neurotoxicity syndrome (127)
Off label use (111)
Pyrexia (75)
Small cell lung cancer (66)
Death (45)
Metastases to central nervous system (28)
Decreased appetite (23)
Dysgeusia (22)
Fatigue (22)
What Other Drugs Cause Disease progression?
RITUXIMAB (7,282)
CYCLOPHOSPHAMIDE (7,100)
DOXORUBICIN (6,165)
VINCRISTINE (5,252)
PREDNISONE (5,096)
BEVACIZUMAB (4,653)
DEXAMETHASONE (4,545)
CARBOPLATIN (4,538)
CAPECITABINE (3,808)
ETOPOSIDE (3,776)
Which TARLATAMAB-DLLE Alternatives Have Lower Disease progression Risk?
TARLATAMAB-DLLE vs TASIGNA
TARLATAMAB-DLLE vs TASIMELTEON
TARLATAMAB-DLLE vs TAVABOROLE
TARLATAMAB-DLLE vs TAXOL
TARLATAMAB-DLLE vs TAXOTERE